Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

Autor: Lin, Simeng, Kennedy, Nicholas A, Saifuddin, Aamir, Sandoval, Diana Mu��oz, Reynolds, Catherine J, Seoane, Rocio Castro, Kottoor, Sherine H, Pieper, Franziska P, Lin, Kai-Min, Butler, David K, Chanchlani, Neil, Nice, Rachel, Chee, Desmond, Bewshea, Claire, Janjua, Malik, McDonald, Timothy J, Sebastian, Shaji, Alexander, James L, Constable, Laura, Lee, James C, Murray, Charles D, Hart, Ailsa L, Irving, Peter M, Jones, Gareth-Rhys, Kok, Klaartje B, Lamb, Christopher A, Lees, Charlie W, Altmann, Daniel M, Boyton, Rosemary J, Goodhand, James R, Powell, Nick, Ahmad, Tariq, CLARITY IBD Study

Publikováno v: Nature Communications, 13, 1, pp. 1379
Nature Communications, 13, 1379
2022, ' Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab ', Nature Communications, vol. 13, no. 1, 1379, pp. 1379 . https://doi.org/10.1038/s41467-022-28517-z

Funder: Royal Devon and Exeter NHS Foundation Trust (Royal Devon & Exeter NHS Foundation Trust); doi: https://doi.org/10.13039/100009745
Funder: Roche (F. Hoffmann-La Roche Ltd); doi: https://doi.org/10.13039/100004337
Funder: Celltrion Hea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9ab1e6b1afed86c7cea0a09ae909d5c
https://doi.org/10.1038/s41467-022-28517-z